Rosuvastatin: An independent analysis of risks and benefits

MedGenMed Medscape General Medicine

Volumn 8, Issue 2, 2006, Pages

  Zipes, Douglas P ^a   Zvaifler, Nathan J ^b   Glassock, Richard J ^c   Gilman, Sid ^d   Muñoz, Alvaro ^e   Gogolak, Victor ^f   Gordis, Leon ^e   Dedon, Peter C ^g   Guengerich, Frederick P ^h   Wasserman, Stephen I ^b   Witztum, Joseph L ^b   Wogan, Gerald N ^g  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f DrugLogic   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ARTICLE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; HEMATURIA; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; META ANALYSIS; MYALGIA; MYOPATHY; NEPHROTOXICITY; PROTEINURIA; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; UNITED STATES; CHEMICALLY INDUCED DISORDER; KIDNEY DISEASE; MUSCLE DISEASE; REVIEW;

FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MUSCULAR DISEASES; PYRIMIDINES; RISK ASSESSMENT; SULFONAMIDES;

EID: 33745216692     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wolfe SM. Dangers of rosuvastatin identified before and after FDA approval. Lancet. 2004;363:2189-2190. Abstract
2. US Department of Health and Human Services. Re Docket No. 2004-P-0013/ CP1. March 11, 2005. Available at: http://www.fda.gov/ohrms/dockets/dockets/04p0113/04p-0113-pdn0001.pdf Accessed June 6, 2006.
3. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing Circulation. 2005;111:3051-3057. Abstract
4. Grundy SM. The issue of statin safety: where do we stand? Circulation. 2005;111:3016-3019.
5. Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 2004;148:e4.
6. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92:23K-29K. Abstract
7. Evans M, Roberts A, Davies S, et al. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments 2004;64:1181-1196. Abstract
8. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs. 2004;4:281-29 Abstract
9. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs. 2004;4:117-138. Abstract
10. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol. 2004;94:882-888. Abstract
11. Chang JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther. 2004;26:1368-1387. Abstract
12. Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Safety. 200-557.
13. Barry M. Rosuvastatin-warfarin drug interaction. Lancet. 2004;363:328.
14. Anonymous. AstraZeneca FDA Advisory Committee Briefing Document. 2003.
15. Anonymous. AstraZeneca Periodic Safety Update Report for Crestor. 2004.
16. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160. Abstract
17. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol. 2000;85:15E-19E. Abstract
18. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92:23K-29K. Abstract
19. Kendrach MG, Kelly FM. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacol 2004;38:1286-1292. Abstract
20. Schuster H. Rosuvastatin - a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical data at 10-40 mg doses in dyslipidemic patients. Cardiol. 2003;99:126-139.
21. Cheng AYY, Leiter LA. Rosuvastatin. J Drug Eval. 2004;2:41-55.
22. Cheng-Lai A. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis. 2003;5:7 Abstract
23. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and ato across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003;91:33-41 Abstract
24. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144:1044-1051. Abstract
25. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88:504-508. Abstract
26. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, a stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-1427. Abstract
27. Deedwania PC, Hunninghake DB, Bays H. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. A Cardiol. 2004;93:18C-26C. Abstract
28. Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozyg familial hypercholesterolemia. Am J Cardiol. 2003;92:1287-1293. Abstract
29. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cho with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002;89:268-275. Abstract
30. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductio Cholesterol Using Rosuvastatin Therapy (MERCURY 1) study. Am Heart J. 2004;147:705-713. Abstract
31. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals Atherosclerosis Suppl. 2004;5:115-121.
32. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am Cardiol. 2003;91:11C-17C. Abstract
33. Strutt K, Caplan R, Hutchison H, Dane A, Blasetto J. More Western hypercholesterolemic patients achieve Japan Atherosclero, Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy. Circ J. 2004;68:107-1 Abstract